Clinical Report: Sentara Brings 1st Minimally Invasive Treatment for Aortic Regurgitation to Virginia

Overview

Sentara Health has introduced the JenaValve Trilogy Transcatheter Heart Valve System, the first FDA-approved minimally invasive treatment for aortic regurgitation in patients with non-calcified valves.

Background

For decades, open-heart surgery was the sole treatment for severe aortic valve disease. The introduction of transcatheter aortic valve replacement (TAVR) has transformed treatment for aortic stenosis, but patients with aortic regurgitation often remained ineligible for traditional TAVR due to the lack of valve calcification. The JenaValve Trilogy offers a new solution for these patients.

Data Highlights

Sentara Heart Hospital completed 30 procedures and screened over 100 patients during the ALIGN-AR clinical trial, which began in March 2022. The JenaValve Trilogy received FDA approval in March 2026.

Key Findings

• Sentara Health is the first health system in Virginia to offer the JenaValve Trilogy for aortic regurgitation.
• The Trilogy valve is specifically designed for patients with symptomatic aortic regurgitation and non-calcified valves.
• Sentara participated in the national ALIGN-AR clinical trial, contributing to the FDA approval of the Trilogy system.
• The new procedure allows for a minimally invasive approach, reducing recovery time compared to traditional surgery.
• Sentara's involvement in clinical trials positions it as a leader in structural heart therapies.

Clinical Implications

The introduction of the JenaValve Trilogy provides a new treatment option for high-risk patients with aortic regurgitation.

Conclusion

The JenaValve Trilogy represents a new treatment option for patients with aortic regurgitation.

Related Resources & Content

1. Barnes-Jewish, Advanced Heart Valve Procedures Expand Treatments for Patients With Limited Options, 2023 -- https://professionals.barnesjewish.org/news/advanced-heart-valve-procedures-expand-treatments-for-patients-with-limited-options
2. Frontiers in Cardiovascular Medicine, Concomitant transcatheter edge-to-edge treatment for mitral regurgitation and the K-Clip system for tricuspid regurgitation: one case report, 2026 -- https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2026.1791302/full
3. Journal of Cardiac Failure, Heterotopic Heart Valve Implantation for Caval Reflux: A Novel Strategy to Bridge the Therapeutic Gap in Severe Tricuspid Regurgitation With Right Heart Failure, 2026 -- https://onlinejcf.com/article/s1071-9164(26)00110-7/fulltext
4. ESC Guidelines, 2025 official slides VHD -- https://www.escardio.org/static-file/Escardio/Guidelines/Products/Slide%20sets/2025/2025%20official%20slides_VHD.pdf
5. FDA, Premarket Approval (PMA) for JenaValve Trilogy -- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P250024
6. PubMed, Effectiveness of Transcatheter Aortic Valve Replacement in Pure Severe Native Aortic Valve Regurgitation: A Systematic Review and Meta-analysis -- https://pubmed.ncbi.nlm.nih.gov/40440534/?utm_source=openai
7. Frontiers in Cardiovascular Medicine — Snare Technique for Valve-in-Valve Transcatheter Aortic Valve Replacement in a Stented Coarctation of the Aorta: A Case Report
8. https://www.escardio.org/static-file/Escardio/Guidelines/Products/Slide%20sets/2025/2025%20official%20slides_VHD.pdf
9. Premarket Approval (PMA)
10. Effectiveness of Transcatheter Aortic Valve Replacement in Pure Severe Native Aortic Valve Regurgitation: A Systematic Review and Meta-analysis - PubMed